orbofiban has been researched along with alanine in 45 studies
| Studies (orbofiban) | Trials (orbofiban) | Recent Studies (post-2010) (orbofiban) | Studies (alanine) | Trials (alanine) | Recent Studies (post-2010) (alanine) |
|---|---|---|---|---|---|
| 48 | 17 | 0 | 24,468 | 512 | 5,581 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.22) | 18.2507 |
| 2000's | 43 (95.56) | 29.6817 |
| 2010's | 1 (2.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferguson, JJ | 1 |
| Adderley, SR; Fitzgerald, DJ | 1 |
| Asai, F; Naganuma, H; Ogawa, T; Sugidachi, A | 1 |
| Schneider, DJ; Sobel, BE; Taatjes, DJ | 1 |
| Cannon, CP; Holmes, MB; Schneider, DJ; Sobel, BE | 1 |
| Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG | 1 |
| Jang, IK; Sabatine, MS | 1 |
| Bozarth, JM; Forsythe, MS; Mousa, SA; Slee, A | 1 |
| McGuire, DK; Newby, LK | 1 |
| Bhatt, DL; Topol, EJ | 1 |
| Cox, D; Crean, P; Fitzgerald, DJ; Quinn, M; Smith, R; Theroux, P | 1 |
| Cannon, CP | 1 |
| Bhatt, DL; Chew, DP | 1 |
| Bhatt, DL; Chew, DP; Sapp, S; Topol, EJ | 1 |
| Bentley, JH; Braunwald, E; Cannon, CP; McCabe, CH; Wilcox, RG | 1 |
| Abood, NA; Anders, RJ; Frederick, LG; Nicholson, NS; Page, JD; Panzer-Knodle, SG; Salyers, AK; Suleymanov, OD; Szalony, JA; Taite, BB | 1 |
| Anders, R; Burns, D; Kleiman, J; Nicholson, N; Wazowicz, B | 1 |
| Braunwald, E; Cannon, CP; Fitzgerald, A; Fitzgerald, DJ; O'Connor, FF; Shields, DC | 1 |
| Abulencia, JP; Konstantopoulos, K; McCarty, OJ; Mousa, SA; Turner, NA | 1 |
| Byrne, CE; Cannon, CP; Fitzgerald, AP; Fitzgerald, DJ; Kenny, D; Moran, B; Muckian, C; O'Neill, PA; Shields, DC | 1 |
| Fitzgerald, A; Fitzgerald, DJ; Muckian, C; O'Byrne, A; O'Neill, A; Shields, DC | 1 |
| Feuerstein, GZ; Wang, X; Zondlo, SC | 1 |
| Barbera, FA; Dorsam, RT; Feuerstein, GZ; Friedman, SM; Gibbs, S; Lauver, A; Savion, N; Varon, D; Wang, H; Wang, X | 1 |
| Abrams, CS; Cines, DB | 1 |
| Aster, RH; Brassard, JA; Cannon, CP; Cooper, RA; Curtis, BR; Ehardt, M; Ferguson, J; Komocsar, W; Kupfer, S; Maurath, C; Swabb, E | 1 |
| Billheimer, JT; He, B; Seiffert, D; Spitz, SM; Stern, AM | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; de Lemos, JA; Gibson, CM; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS | 1 |
| Billheimer, JT; He, B; Kieras, CJ; Pedicord, DL; Seiffert, D; Stern, AM | 1 |
| Bentley, J; Blatt, A; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Cotter, G; Kaluski, E; Krakover, R; Lewis, B; Marmor, A; McCabe, CH; Michowitz, Y; Milo, O; Reisin, L; Vered, Z; Zimlichman, R | 1 |
| Ayanian, S; Braunwald, E; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Rifai, N; Sabatine, MS | 1 |
| Feuerstein, GZ; Friedman, SM; Gibbs, SK; Racanelli, AL; Seiffert, DA; Zondlo, SC | 1 |
| Anders, RJ; Baracioli, LM; Cannon, CP; Nicolau, JC; Ramires, JA; Serrano, CV; Venturinelli, M | 1 |
| Bentley, JH; Cannon, CP; Charlesworth, A; Kovar, D; Rogers, WJ | 1 |
| Chakrabarti, S; Clutton, P; Cox, D; Freedman, JE; Mascelli, MA; Varghese, S | 1 |
| Braunwauld, E; Cannon, CP; Cantor, WJ; Charlesworth, A; Goodman, SG; Langer, A; Murphy, SA | 1 |
| Abernethy, DR; Cox, D; Fitzgerald, DJ; Mager, DE; Shirey, JD | 1 |
| Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE | 1 |
| Atar, S; Birnbaum, Y; Cannon, CP; Murphy, SA; Rosanio, S; Uretsky, BF | 1 |
| Buros, JL; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS | 1 |
| Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM | 1 |
| Connor, JH; Connor, RF; Hantgan, RR; Mousa, SA; Stahle, MC | 1 |
| Braunwald, E; Buros, J; Cannon, CP; Gibson, CM; Kirtane, AJ; McCabe, CH; Morrow, DA; Ray, KK; Rifai, N | 1 |
| Alonso Castillejos, N; García Iglesias, R; Inglada-Galiana, L; Martín Gil, FJ; San Miguel Hernández, A | 1 |
| Braunwald, E; Cannon, CP; de Lemos, JA; McCabe, CH; Morrow, DA; Murphy, S; Rifai, N; Sabatine, MS; Scirica, BM; Wiviott, SD | 1 |
| Cannon, CP; Cox, D; Fitzgerald, DJ; Jneid, H; Maree, AO; Ryan, J; Shields, DC; Vangjeli, C | 1 |
7 review(s) available for orbofiban and alanine
| Article | Year |
|---|---|
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
Oral platelet glycoprotein IIb/IIIa inhibition.
Topics: Alanine; Angina, Unstable; Aspirin; Benzamidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Myocardial Infarction; Oximes; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Syndrome; Treatment Outcome | 2000 |
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Alanine; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Drug Therapy, Combination; Eptifibatide; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Tirofiban; Tyrosine | 2000 |
Oral glycoprotein IIb/IIIa antagonists in coronary artery disease.
Topics: Administration, Oral; Alanine; Benzamidines; Coronary Disease; Humans; Integrins; Oximes; Piperidines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Topics: Administration, Oral; Alanine; Aspirin; Benzamidines; Clinical Trials, Phase III as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Oximes; Piperidines; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |
Xemilofiban/orbofiban: insight into drug development.
Topics: Alanine; Angina, Unstable; Animals; Benzamidines; Bleeding Time; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coronary Thrombosis; Drug Evaluation, Preclinical; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines | 2001 |
Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis.
Topics: Abciximab; Alanine; Antibodies, Monoclonal; Autoimmunity; Benzamidines; Humans; Immunoglobulin Fab Fragments; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Pyrrolidines; Thrombocytopenia; Thrombosis | 2002 |
17 trial(s) available for orbofiban and alanine
| Article | Year |
|---|---|
Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction.
Topics: Acute Disease; Administration, Oral; Alanine; Blood Platelets; Coronary Thrombosis; Fibrinogen; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Recurrence; Thrombolytic Therapy; Treatment Outcome | 2000 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heparin; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Stroke; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2000 |
Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes.
Topics: Acute Disease; Aged; Alanine; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines | 2000 |
Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators.
Topics: Aged; Alanine; Angina, Unstable; Female; Follow-Up Studies; Humans; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrrolidines; Risk Factors; Survival Rate | 2001 |
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
Topics: Aged; Alanine; Angina, Unstable; Antigens, Human Platelet; Aspirin; Double-Blind Method; Female; Genetic Variation; Genotype; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pyrrolidines | 2001 |
The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists.
Topics: Alanine; Coronary Disease; Genotype; Glycoproteins; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pyrrolidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Stroke; Thrombosis; Treatment Outcome | 2002 |
Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease.
Topics: Alanine; Alleles; Angina, Unstable; Collagen; Collagen Type III; Coronary Disease; Cross-Sectional Studies; Extracellular Matrix; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hemorrhage; Heterozygote; Humans; Minisatellite Repeats; Myocardial Infarction; Myocardial Ischemia; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pyrrolidines; Treatment Outcome | 2002 |
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology.
Topics: Acute Disease; Alanine; Autoantibodies; Autoimmunity; Benzamidines; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Pyrrolidines; Risk Factors; Thrombocytopenia | 2002 |
Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Alanine; Biomarkers; Chemokine CCL2; Cohort Studies; Confounding Factors, Epidemiologic; Coronary Disease; Female; Humans; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Pyrrolidines; Randomized Controlled Trials as Topic; Reference Values; Risk Assessment; Risk Factors; Survival Analysis; Time; Treatment Outcome | 2003 |
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysi
Topics: Aged; Alanine; Aspirin; Cerebrovascular Disorders; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Multivariate Analysis; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Pyrrolidines; Regression Analysis; Risk Factors; Treatment Outcome | 2003 |
Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes.
Topics: Acute Disease; Alanine; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Neutrophil Activation; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Superoxides; Treatment Outcome | 2003 |
Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial.
Topics: Aged; Alanine; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Coronary Angiography; Coronary Artery Bypass; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Pyrrolidines; Risk Factors; Stents; Survival Analysis | 2005 |
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Proportional Hazards Models; Pyrrolidines; Risk Factors; Stroke; Syndrome; Thrombolytic Therapy | 2006 |
Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Alanine; Biomarkers; Fatty Acid-Binding Proteins; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Odds Ratio; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Pyrrolidines; Risk Factors; Troponin I | 2006 |
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombocytopenia; Thrombosis | 2006 |
Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18.
Topics: Aged; Alanine; Biomarkers; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Diabetic Angiopathies; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Myocardial Ischemia; Myocarditis; Pyrrolidines; von Willebrand Factor | 2007 |
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Topics: Acute Disease; Aged; Alanine; Angina Pectoris; Angina, Unstable; C-Reactive Protein; Coronary Disease; Female; Follow-Up Studies; Heart Failure; Humans; Male; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Recurrence; Risk; Syndrome | 2007 |
21 other study(ies) available for orbofiban and alanine
| Article | Year |
|---|---|
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal; Aspirin; Benzamidines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Disease; Dalteparin; Defibrillators, Implantable; Double-Blind Method; Enalapril; Endothelial Growth Factors; Fatty Acids, Omega-3; Guanidines; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Laser Therapy; Lymphokines; Metoprolol; Multicenter Studies as Topic; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pyrrolidines; Randomized Controlled Trials as Topic; Simvastatin; Sodium-Hydrogen Exchangers; Stents; Sulfones; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vitamin E | 1999 |
Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation.
Topics: Alanine; Animals; Apoptosis; Benzamidines; Caspase 3; Caspases; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium; Enzyme Activation; Enzyme Precursors; Eptifibatide; Humans; Kinetics; Ligands; Mice; Myocardium; Oligopeptides; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Rats; Rats, Wistar; Time Factors; Umbilical Veins | 2000 |
Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
Topics: Adenosine Diphosphate; Administration, Oral; Alanine; Animals; Arteriovenous Shunt, Surgical; Aspirin; beta-Alanine; Bleeding Time; Collagen; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Guinea Pigs; Hemostasis; Hypercholesterolemia; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis; Urea | 2000 |
Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Topics: Abciximab; Alanine; Antibodies, Monoclonal; Antigens, CD; Blood Platelets; Dose-Response Relationship, Drug; Fibrinogen; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Microscopy, Confocal; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Protein Binding; Pyrrolidines; Tetraspanin 30 | 2000 |
Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
Topics: Abciximab; Alanine; Amidines; Analysis of Variance; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Calcium; Citric Acid; Eptifibatide; Fibrinogen; Heparin; Humans; Immunoglobulin Fab Fragments; Iodine Radioisotopes; Isoxazoles; Peptides; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Pyrrolidines; Tirofiban; Tyrosine | 2000 |
Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials.
Topics: Alanine; Angina, Unstable; Benzamidines; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Syndrome; Treatment Outcome | 2000 |
Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist.
Topics: Administration, Oral; Alanine; Animals; Biological Availability; Dogs; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines | 2001 |
Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
Topics: Alanine; Amidines; Blood Platelets; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Isoxazoles; Models, Biological; Platelet Adhesiveness; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis | 2002 |
Effects of orally active glycoprotein IIb/IIIa antagonists on platelet CD40 ligand (CD154) expression and platelet-heteroaggregate formation.
Topics: Administration, Oral; Alanine; Amidines; CD40 Ligand; Cell Adhesion; Dose-Response Relationship, Drug; Humans; Isoxazoles; Leukocytes; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proteins; Pyrrolidines; Receptors, Thrombin | 2002 |
Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Topics: Abciximab; Alanine; Amidines; Analysis of Variance; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cell Aggregation; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Isoxazoles; Peptides; Platelet Activation; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Rheology; Shear Strength; Temperature; Tirofiban; Tyrosine | 2002 |
Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
Topics: Alanine; Amidines; Benzodiazepines; Blood Platelets; Humans; In Vitro Techniques; Isoxazoles; Oximes; P-Selectin; Piperidines; Platelet Adhesiveness; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis | 2002 |
Regulation of clot retraction by glycoprotein IIb/IIIa antagonists.
Topics: Abciximab; Alanine; Amidines; Antibodies, Monoclonal; Blood Platelets; Clot Retraction; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Isoxazoles; Phosphorylation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Sulfonamides; Tyrosine | 2002 |
Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes.
Topics: Acute Disease; Alanine; Biomarkers; Coronary Disease; Female; Humans; Immunoassay; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Syndrome; Troponin I | 2003 |
Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro.
Topics: Adenosine Diphosphate; Alanine; Blood Platelets; Humans; In Vitro Techniques; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Time Factors | 2003 |
Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes?
Topics: Acute Disease; Alanine; Female; Heart Rate; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prognosis; Pyrrolidines; Syndrome | 2004 |
Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Topics: Abciximab; Alanine; Antibodies, Monoclonal; Blood Platelets; Calcium; Humans; Immunoglobulin Fab Fragments; Leukocytes, Mononuclear; NADPH Oxidases; Nitric Oxide; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Superoxides | 2004 |
Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network.
Topics: Alanine; Angina, Unstable; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Neural Networks, Computer; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Reproducibility of Results | 2005 |
Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.
Topics: Acute Disease; Administration, Oral; Aged; Alanine; Anticoagulants; Aspirin; Coronary Disease; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Patient Discharge; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Retrospective Studies; Risk Assessment; Severity of Illness Index; Syndrome | 2006 |
AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists.
Topics: Administration, Oral; Alanine; Amidines; Binding, Competitive; Blood Platelets; Dimerization; Dose-Response Relationship, Drug; Eptifibatide; Female; Fibrinogen; Humans; In Vitro Techniques; Injections, Intravenous; Intercellular Signaling Peptides and Proteins; Isoxazoles; Kinetics; Male; Models, Molecular; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Protein Conformation; Pyrrolidines; Reference Values; Structure-Activity Relationship; Tirofiban; Tyrosine | 2007 |
[Soluble CD40 ligand: a potential marker of cardiovascular risk].
Topics: Abciximab; Acute Coronary Syndrome; Alanine; Angina, Unstable; Animals; Antibodies, Monoclonal; Anticoagulants; Aspirin; Atherosclerosis; Biomarkers; Cardiovascular Diseases; CD40 Ligand; Chromosomes, Human, X; Clinical Trials as Topic; Disease Models, Animal; Female; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Mice; Platelet Activation; Platelet Aggregation Inhibitors; Prognosis; Pyrrolidines; Risk Factors; Thrombosis | 2007 |
G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trial.
Topics: Alanine; Heart Diseases; Heterotrimeric GTP-Binding Proteins; Humans; Myocardial Infarction; Polymorphism, Genetic; Pyrrolidines; Thrombolytic Therapy | 2010 |